Search
EHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma
Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev
This meeting will be held in English and offer a simultaneous translation to Russian.
EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia
Dates: April 12-14, 2018
Location: Barcelona, Spain
Chair: N Gökbuget
Co-chairs: R Bassan, H Dombret, A Fielding, R Foà, D Hoelzer, JM Ribera
EHA and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia.…
EHA25 Virtual | News Room
Welcome to the news room of EHA25 Virtual where you can find the most relevant news items.
Read moreEHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms
Dates: October 12-14, 2017
Location: Budapest, Hungary
Chairs: C Harrison, JJ Kiladjian
EHA and the EHA Scientific Working Group on Myeloproliferative Neoplasms are organizing this EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms.
Highlights of Past EHA (HOPE) Asia 2023
EHA joined forces with the Indian Society of Hematology & Blood Transfusion (ISHBT) to organize the 5th edition of the Highlights of Past EHA (HOPE) Asia 2023 meeting.
Read moreEHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias
Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia
Registration is now open
OverviewThe EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus…
ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models
November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- »